Position in HIMS
as of Mar 31, 2026
· filed Apr 23, 2026
Position Value
$6,954
New position
Shares Held
335
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026SJS Investment Consulting Inc. holds $494,457 across 30 Drug Manufacturers - Specialty & Generic names. HIMS ranks #8 (1.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HROW |
Harrow, Inc.
|
6,073 | $214,133 | |
| 2 | ESPR |
Esperion Therapeutics, Inc.
|
25,000 | $68,500 | |
| 3 | ZTS |
Zoetis Inc.
|
465 | $54,967 | |
| 4 | NBIX |
Neurocrine Biosciences Inc
|
341 | $44,923 | |
| 5 | ELAN |
Elanco Animal Health Inc
|
1,424 | $34,076 | |
| 6 | UTHR |
UNITED THERAPEUTICS Corp
|
51 | $30,241 | |
| 7 | TAK |
Takeda Pharmaceutical Co Ltd
|
1,468 | $27,187 | |
| 8 | HIMS |
Hims & Hers Health, Inc.
This page
|
335 | $6,954 |
All Filings in HIMS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $6,954 | 335 | Shares | Sole | 2026-04-23 | |
| No filing history on record for this holder in this stock. | ||||||